ABSTRACT
The present study shows that recombinant human megakaryocyte growth and development factor (r-HuMGDF) behaves both as a megakaryocyte colony stimulating factor and as a differentiation factor in human progenitor cell cultures. Megakaryocyte colony formation induced with r-HuMGDF is synergistically affected by stem cell factor but not by interleukin 3. Megakaryocytes stimulated with r-HuMGDF demonstrate progressive cytoplasmic and nuclear maturation. Measurable levels of megakaryocyte growth and development factor in serum from patients undergoing myeloablative therapy and transplantation are shown to be elaborated in response to thrombocytopenic stress. These data support the concept that megakaryocyte growth and development factor is a physiologically regulated cytokine that is capable of supporting several aspects of megakaryopoiesis.
Subject(s)
Hematopoiesis/drug effects , Megakaryocytes/cytology , Thrombocytopenia/blood , Thrombopoietin/pharmacology , Adult , Cell Differentiation/drug effects , Cell Division/drug effects , Colony-Forming Units Assay , Humans , In Vitro Techniques , Interleukin-3/pharmacology , Recombinant Proteins , Stem Cell FactorABSTRACT
In 1972 we reported myocardial revascularization of 130 patients using multiple sequential aortocoronary anastomoses to a single saphenous vein ]1]. Of the 122 survivors described in that report, 121 (99%) have been followed an additional 3 years. Twelve deaths occurred during the interval. The 110 currently followed patients represent 290 anastomoses; 54 have been studied angiographically since operation. Angiographic patency at 3 years in the studied group (18) was 70%. These figures exceed our follow-up data for 135 patients revascularized during the same period using individual vein grafts. Comparison of life table survival curves demonstrates this result. We believe the improved patency and decreased operating time that have resulted from employing this technique have outweighed the likelihood of a proximal stenosis causing closure of the whole graft system. We continue to use this technique in combination with internal mammary artery grafts in the management of multiple-vessel coronary disease. Good early results using this technique have been reported by other authors [2, 3, 5].